SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-066904
Filing Date
2023-08-14
Accepted
2023-08-14 15:24:09
Documents
14
Period of Report
2023-08-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea183077-8k_emmaus.htm   iXBRL 8-K 26404
2 AUGUST 14, 2023 PRESS RELEASE ea183077ex99-1_emmaus.htm EX-99.1 46593
3 GRAPHIC ex99-1_001.jpg GRAPHIC 8580
  Complete submission text file 0001213900-23-066904.txt   261677

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE emma-20230814.xsd EX-101.SCH 3045
5 XBRL LABEL FILE emma-20230814_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE emma-20230814_pre.xml EX-101.PRE 22379
8 EXTRACTED XBRL INSTANCE DOCUMENT ea183077-8k_emmaus_htm.xml XML 3039
Mailing Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503
Business Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503 310-214-0065
Emmaus Life Sciences, Inc. (Filer) CIK: 0000822370 (see all company filings)

IRS No.: 870419387 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35527 | Film No.: 231169135
SIC: 2834 Pharmaceutical Preparations